PAYLESS COMPOUNDERS, LLC

FDA Regulatory Profile

PAYLESS COMPOUNDERS, LLC appears in FDA public data with 1 recall, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0471-2026, Class II) was initiated on March 6, 2026.

Summary

Total Recalls
1
510(k) Clearances
0
Inspections
0
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-0471-2026Class IISemaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, NorthweMarch 6, 2026